A positron emission tomography (PET) imaging agent could show, ahead of time, whether a specific treatment is likely to be effective for major depressive disorder (MDD)—a debilitating condition that affects more than 14 million Americans. No such marker is currently available in clinical psychiatry. The study is featured in the April issue of The Journal of Nuclear Medicine.  {read more here}

An artificial intelligence (AI) technique developed at Massachusetts General Hospital (MGH) can enhance the reconstruction process for medical images, decreasing radiation dose in x-ray, CT, and PET scans and hastening MRI acquisition, according to research published online March 21 in Nature. {read more here}

“PET amyloid has historically largely been considered a positive or negative diagnostic test,” McMillan told MedPage Today. “But this study suggests that quantitative measurements of PET amyloid in pre-symptomatic individuals can be informative.” {read more here}

A new imaging agent for positron emission tomography, or PET, scans could help assess and treat people with various neurological diseases, including Alzheimer’s and Parkinson’s diseases and multiple sclerosis, according to new research. {read more here}